Avamys (Fluticasone Furoate)
Is It Right for You?
A complete guide to Avamys (Fluticasone Furoate) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Avamys (Fluticasone Furoate)?
Avamys is a branded intranasal corticosteroid nasal spray containing fluticasone furoate as its active ingredient. It belongs to the glucocorticoid class of medicines and acts locally within the nasal passages to suppress inflammation and relieve the full spectrum of allergic rhinitis symptoms. Fluticasone furoate is a next-generation synthetic corticosteroid molecule distinguished by its exceptionally high affinity for glucocorticoid receptors and an extremely low systemic bioavailability following intranasal administration — approximately 0.5% — making it one of the most locally selective intranasal steroids available in the UK.
Avamys is manufactured by GlaxoSmithKline (GSK) and is supplied as a 27.5 mcg-per-actuation aqueous nasal spray suspension. Each bottle delivers 120 metered actuations. It is licensed for use in adults and children aged 6 years and over.
Fluticasone furoate should not be confused with fluticasone propionate, a related but chemically distinct molecule used in formulations such as Flixonase nasal spray and Flixotide inhaler. Fluticasone furoate has a higher glucocorticoid receptor binding affinity and longer tissue retention compared to fluticasone propionate, contributing to its once-daily dosing profile and potent nasal activity.
What Conditions Does Avamys Treat?
Avamys is prescribed for:
Avamys is first-line treatment for seasonal allergic rhinitis — commonly known as hayfever — triggered by airborne allergens including tree pollen (spring), grass pollen (early summer), and weed pollen (late summer). It reliably addresses all four cardinal nasal symptoms: congestion, runny nose (rhinorrhoea), sneezing, and nasal itching. Clinical trial data also demonstrate benefit on ocular symptoms such as itchy, watery, and red eyes, which frequently accompany hayfever.
Perennial allergic rhinitis causes year-round nasal symptoms driven by persistent indoor allergens including house dust mites, pet dander (cats, dogs, horses), mould spores, and cockroach allergens. Avamys provides consistent symptom control when used as a regular daily treatment throughout the year.
Some clinicians prescribe intranasal corticosteroids off-label for non-allergic or vasomotor rhinitis, a condition characterised by chronic nasal symptoms triggered by environmental irritants (perfumes, smoke, cold air, humidity changes) rather than allergens. Evidence is more limited than for allergic disease, but patients with a mixed or inflammatory pattern may derive benefit.
Intranasal corticosteroids are central to the medical management of nasal polyps. While Avamys does not carry a specific UK licence for this indication, clinicians may use it as part of a broader management strategy, particularly as maintenance therapy following endoscopic sinus surgery or in patients with mild polyposis not yet requiring surgical intervention.
Avamys is a preventive treatment and does not work rapidly enough to be used as a rescue medication during acute allergic episodes. For immediate symptom relief, an oral antihistamine or decongestant is more appropriate.
How Does Avamys Work?
Fluticasone furoate exerts its therapeutic effect by penetrating nasal mucosal cells and binding with high affinity to intracellular glucocorticoid receptors. The resulting drug-receptor complex translocates to the cell nucleus, where it modulates transcription of genes governing the inflammatory response.
Key pharmacological actions include: suppression of pro-inflammatory cytokines (including IL-4, IL-5, and IL-13), inhibition of eosinophil recruitment and activation within the nasal mucosa, reduction in mast cell degranulation, decreased leukotriene and prostaglandin synthesis, and downregulation of mucus-secreting goblet cell hyperplasia. Collectively, these actions reduce mucosal oedema, hypersecretion, and neurogenic irritation — addressing all major symptomatic pathways simultaneously.
Because of fluticasone furoate's near-negligible systemic absorption, these potent anti-inflammatory effects are confined almost entirely to the nasal tissues, with minimal systemic corticosteroid activity even with long-term daily use at licensed doses.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Correct technique is critical both for therapeutic efficacy and to minimise the risk of nasal septum injury. The patient should gently blow their nose before use, then tilt the head slightly forward. Holding the bottle upright, insert the nozzle into one nostril and angle it away from the nasal septum (towards the outer wall of the nasal passage — do not point it towards the middle of the nose). Depress the pump once while inhaling gently and steadily through the nose. Repeat in the other nostril. Avoid sniffing forcefully immediately after administration as this reduces mucosal contact time. Wipe and rinse the nozzle with clean water after each use to prevent blockage.
Priming: Before first use, shake the bottle well and spray to waste 6 times until a fine, even mist appears. Reprime with 2 sprays to waste if the device has not been used for 30 or more consecutive days.
When to Expect Results
Some symptomatic improvement may be noticed within 8 hours of the first dose. However, maximum therapeutic benefit develops gradually over 1 to 2 weeks of consistent daily use. Patients should be counselled to use Avamys every day regardless of symptom fluctuation, rather than only on symptomatic days, to maintain mucosal anti-inflammatory control.
Side Effects of Avamys
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Nosebleeds (epistaxis)
- Nasal irritation or burning
- Dryness inside the nose
- Headache
- Severe allergic reaction — swelling of face, lips, or throat, difficulty breathing
- Nasal septum perforation — persistent nose pain, bleeding, or whistling sound when breathing
- Vision changes — blurred vision (rare; may indicate glaucoma or cataracts with long-term use)
- Adrenal suppression (rare) — fatigue, weakness (with prolonged high-dose use)
Persistent, frequent, or heavy nosebleeds should prompt clinical review. Ensure correct technique is being used.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Avamys
Important Warnings
Persistent, frequent, or heavy epistaxis should prompt clinical review. Ensure correct technique is being used. Persistent unilateral nosebleeds unrelated to the spray should always be investigated to exclude other causes.
Report any nasal pain, persistent crusting, or whistling sounds when breathing to your clinician promptly. Perforation is rare but more likely with incorrect administration technique.
Inadvertent ocular exposure can cause irritation. If spray contacts the eyes, rinse thoroughly with water.
Patients taking ritonavir, cobicistat, itraconazole, or similar drugs must inform their clinician before commencing Avamys. An alternative anti-inflammatory or additional monitoring may be required.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Avamys FAQs
Yes. Avamys is safe and appropriate for long-term daily use when prescribed appropriately. Unlike oral corticosteroids, intranasal steroids at recommended doses carry negligible systemic absorption and are considered safe for continuous maintenance therapy in chronic allergic rhinitis. Many patients with perennial rhinitis use an intranasal corticosteroid year-round without adverse effects. In patients with seasonal rhinitis only, treatment may be started before the relevant pollen season and discontinued after it ends.
Some improvement in nasal symptoms may be noticeable within 8 hours of the first dose, particularly in terms of congestion. However, the full therapeutic benefit — particularly for sneezing, rhinorrhoea, and nasal itching — is typically established after 1 to 2 weeks of consistent daily use. Patients should not judge the effectiveness of Avamys after only one or two doses.
Avamys is licensed for children aged 6 years and over. Children aged 6 to 11 years should use one spray per nostril once daily. If symptoms remain inadequately controlled, the dose can be increased to two sprays per nostril, but it should be reduced back to one spray as soon as symptoms are well managed. Avamys is not licensed for children under 6 years of age and should not be used in this age group.
Both are fluticasone-based nasal sprays, but they contain different molecules. Avamys contains fluticasone furoate (27.5 mcg per actuation), while Flixonase contains fluticasone propionate (50 mcg per actuation). Fluticasone furoate has a higher glucocorticoid receptor affinity and lower systemic bioavailability than fluticasone propionate. In clinical practice both are effective for allergic rhinitis; the choice between them is generally guided by availability, tolerability, and clinician preference.
Yes. Avamys and antihistamines (oral or intranasal) have complementary mechanisms of action and can be used simultaneously. This combination is frequently recommended in patients with moderate-to-severe allergic rhinitis where monotherapy provides insufficient relief. There is no pharmacokinetic interaction between Avamys and antihistamines.
Avamys should only be used during pregnancy if clearly necessary and if the benefit outweighs the potential risk. The systemic absorption after nasal administration is very low, which reduces the likelihood of meaningful foetal exposure. If nasal symptoms during pregnancy are significantly impacting quality of life or sleep, a clinician can assess whether treatment is appropriate and advise on the lowest effective dose.
If a dose is accidentally swallowed rather than administered nasally, no specific action is required. The systemic bioavailability of fluticasone furoate following oral ingestion is very low (less than 1%), so swallowed doses are unlikely to produce any meaningful systemic effect. Continue using the spray as prescribed.
Weight gain is associated with prolonged systemic corticosteroid use. Given the negligible systemic absorption of fluticasone furoate from intranasal administration, weight gain is not an expected or commonly reported side effect of Avamys at licensed doses.